These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 3518753)

  • 1. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA; Lotze MT
    Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
    [No Abstract]   [Full Text] [Related]  

  • 2. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
    Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
    [No Abstract]   [Full Text] [Related]  

  • 5. Natural killer cells and tumor immunity: 1987.
    Hiserodt JC; Herberman RB
    Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
    [No Abstract]   [Full Text] [Related]  

  • 6. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
    Rosenberg S
    J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy of cancer: the end of the beginning?
    Durant JR
    N Engl J Med; 1987 Apr; 316(15):939-41. PubMed ID: 3493434
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo kinetics of murine lymphoid cells: in relation to local adoptive cancer immunotherapy.
    Yamasaki N; Kan N; Inamoto T; Nakayama N; Nio Y; Hori T
    Nihon Geka Hokan; 1984 Jan; 53(1):67-78. PubMed ID: 6333856
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
    Robak T
    Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
    Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
    Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
    [No Abstract]   [Full Text] [Related]  

  • 11. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
    Dosne Pasqualini C; Laguens RP
    Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E; Chriqui-Zeira E; Kyriazis AP
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interleukin-2 and cancer immunotherapy].
    Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
    Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
    [No Abstract]   [Full Text] [Related]  

  • 14. Heterogeneity of cytotoxic lymphocytes potentially relevant for cellular immunotherapy of cancer: implications for designing clinical strategies.
    Triebel F; Hercend T
    Prog Clin Biol Res; 1987; 244():207-11. PubMed ID: 3498949
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of cancer with lymphokine-activated killer cells and interleukin-2.
    N Engl J Med; 1987 Oct; 317(15):961-3. PubMed ID: 3498120
    [No Abstract]   [Full Text] [Related]  

  • 16. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
    Rosenberg SA
    Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary: potential of interleukin-2 for the therapy of cancer.
    Herberman RB
    J Biol Response Mod; 1984 Oct; 3(5):527-32. PubMed ID: 6389778
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA
    Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of new immunologic approaches to cancer therapy.
    Rosenberg SA
    Blood Purif; 1988; 6(2):69-76. PubMed ID: 3293619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.